Mar 31, 2020

Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro

BioRxiv : the Preprint Server for Biology
Karl Jonas HollensteinerNicasio Mancini


While the SARS-CoV-2 pandemic is hardly hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 cells. This strongly suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Positioning Attribute
Midline (Qualifier Value)
Midline Cell Component
Domestic Polecats
Visual Stimulus
Maximum Likelihood Estimation

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

Nippon Ganka Gakkai zasshi
Mineo KondoHiroko Terasaki
The British Journal of Ophthalmology
A G Lee
Archives of Ophthalmology
M Frenkel
Retinal Cases & Brief Reports
Michael F Marmor
The Journal of Pharmacology and Experimental Therapeutics
© 2020 Meta ULC. All rights reserved